IO 312
Alternative Names: IO-312Latest Information Update: 13 Jun 2023
At a glance
- Originator University of Texas Health Science Center at Houston; University of Texas Southwestern Medical Center
- Developer Immune-Onc Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB4 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in cancer presented at the114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 12 Oct 2022 Preclinical trials in Haematological malignancies in USA (unspecified route) Before October 2022 (Immune-Onc Therapeutics pipeline, October 2022)
- 06 Apr 2017 Immune-Onc Therapeutics enters into a research agreement with University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center to discover and develop biotherapeutics to modulate the immune system for Cancer